Get in Touch

To determine strategies for maximising price, reimbursement and market access (PRMA) potential, considering the competitive landscape and different data scenarios

  • Access Strategy, Price Optimisation

Client Challenge

A large pharma developed three evidence scenarios for their investigational oncology asset informed by available clinical data.

The company wanted to understand price and access potential for these scenarios, along with optimisation 
strategies to implement in major European markets.

P4A Solution

Possible health technology assessment (HTA) outcomes and pricing expectations were explored with payer experts from Germany, France and Spain.

Hypotheses were tested considering the expected benefit over clinical comparators under each evidence scenario (downside, base case and upside), and the predicted current and future price comparators (direct and indirect).

The Successful Outcome​

  • We informed pricing expectations in the scope markets and identified possible levers to maximise price potential.
  • Through investigating possible PRMA outcomes, our clients’ expectations for each evidence scenario were informed to assist their preparation for all eventualities during payer assessments and price negotiations, while awaiting the final data readout.

Need more details?

Do you want to learn more about the successful outcome for this case study? Are you interested in P4A Services or just want to say Hi?

get in touch

Explore other case studies

Understand evidence requirements beyond clinical trial data for launching an orphan drug in Türkiye & the GCC

  • Access Strategy

Optimising the PRMA potential of an orphan oncology asset in EU4 + UK and Japan

  • Price Optimisation, Access Strategy
p4a-logo-small-retina-white

We are award winning global experts in access for orphan drugs and Cell and Gene Therapies.

Twitter Instagram Youtube Linkedin

About

Services

Insights

Case Studies

Contact

P4A Services

For all access and Rare Disease related overview enquiries